Day: July 1, 2020

Á útboðsdegi, milli kl. 10:30 og 11:00, fer fram útboð hjá Lánamálum ríkisins á ríkisbréfum í þeim flokkum, með þeim ISIN númerum og með þeim gjalddögum sem fram koma í töflunni hér að ofan. Greiðsla fyrir ríkisbréfin þarf að berast Seðlabankanum fyrir kl. 14:00 á uppgjörsdegi og verða bréfin afhent rafrænt sama dag. Um 10% viðbót sjá 6. gr. í almennum útboðskilmálum ríkisbréfa.Til nánari upplýsinga er að öðru leyti vísað til heimasíðu Lánamála ríkisins, þ.e. vegna lýsingar skuldabréfaflokksins og almennra útboðsskilmála ríkisbréfa.Nánari upplýsingar veitir Laufey Ómarsdóttir, Lánamálum ríkisins í síma 569 9631.

LiiteOVARO_1.7_trades

LiiteVINCIT_1.7_trades

Se vedhæftedeVedhæftet filEsoft_First-North_139_Generalforsamlingsprotokollat_Ekstraordinær GF 2020

LiiteINVEST_1.7_trades

AUSTIN, Texas, July 01, 2020 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH) (“ASPIRA”), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that investors, including certain affiliates of Jack W. Schuler, ASPIRA’s largest stockholder, have agreed to purchase approximately $11 million of unregistered shares of ASPIRA’s common stock in a private placement at a price of $3.50 per share.The closing of the private placement is expected to occur on July 6, 2020, subject to customary closing conditions. At the closing, ASPIRA will receive approximately $11 million in gross proceeds, before transaction costs. ASPIRA intends to use the net proceeds from the private placement for sales and marketing, working capital and other general corporate purposes, including investing in additional...

SANTA CLARA, Calif., July 01, 2020 (GLOBE NEWSWIRE) — Borqs Technologies, Inc. (Nasdaq: BRQS), (the “Company”, or “Borqs”), a global leader in embedded software and products for the Internet of Things (IoT) industry, announced that due to travel restrictions and lockdown through June 30th related to the COVID-19 pandemic, staff of our Beijing based accounting department as well as our New York based auditor had not been able to travel freely within China and India, and from the U.S. to these two countries.  Our China office had been very much affected as Beijing saw a resurgence of the COVID-19 virus recently. The Company was not able to complete its financial audit for the year ended December 31, 2019 and file the required annual report on Form 20-F by the deadline of June 30, 2020.  As a result, the Company is not in compliance...

HAMILTON, N.J., July 01, 2020 (GLOBE NEWSWIRE) — First Bank (Nasdaq Global Market: FRBA) invites participation in a conference call to discuss the Company’s financial and operating performance during its second quarter ended June 30, 2020.Patrick L. Ryan, President and CEO, Stephen F. Carman, Executive Vice President and CFO, Peter J. Cahill, Executive Vice President and Chief Lending Officer and Emilio Cooper, Executive Vice President and Chief Deposit Officer will provide an overview of second quarter 2020 results. The management presentation typically lasts approximately fifteen minutes, followed by investor questions and discussion. The Company’s second quarter results will be released after the market closes on July 27, 2020, and will also be available in the “Investor Relations” section of the Company’s website. Conference...

Company Completed is Acquisition of 51% of CBD Imports Pty Ltd.MELBOURNE, Australia, July 01, 2020 (GLOBE NEWSWIRE) — Kibush Capital Corporation (OTC:DLCR) (the “Company”) announced today the company has completed its acquisition of 51% of CBD Imports Pty Ltd. CBD Imports Pty Ltd has been granted a CBD licence by the Australian Government to import CBD into Australia, and a CBD Distribution licence by the Victorian State Government, with access to export to the Asian Pacific.These Licences allow the company to begin immediately importing CBD products into Australia and hit the ground running. Through this targeted acquisition, the company plans to advance its operations into the CBD market in order to increase revenues and shareholder value. The company plans to update shareholders shortly on the line-up of products the company...

ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-daily LDL-cholesterol lowering medicine, was published in the Journal of the American Medical Association (JAMA) Cardiology.  The four Phase 3 clinical studies evaluated the efficacy and safety of NEXLETOL versus placebo in 3623 patients with hypercholesterolemia while receiving stable lipid-lowering therapy and at high cardiovascular risk or with hypercholesterolemia and statin intolerance.  NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering...